文献速递青光眼

癌症诊断后青光眼患者用药依从性下降

Medication Adherence in Patients With Glaucoma After Cancer Diagnosis.
PubMed 文献 · Am J Ophthalmol · 2020-01-13

这项基于人群的队列研究纳入确诊青光眼且年龄≥20岁的患者,排除青光眼确诊2年内发生癌症或癌症确诊后2年内死亡者,比较癌症患者与匹配无癌症患者的用药持有比(MPR)。结果显示癌症组1年间隔MPR为0.379,无癌症组为0.313,癌症诊断后1年间隔MPR下降17.4%(P < .001),2年间隔和2年平均间隔分别下降10.4%和9.21%(均P < .001)。结论认为癌症诊断导致青光眼患者用药依从性降低。

要点

  • 癌症诊断后青光眼患者1年间隔MPR下降17.4%(P < .001)。
  • 癌症组1年间隔MPR为0.379,无癌症组为0.313。
  • 2年间隔和2年平均间隔MPR分别下降10.4%和9.21%(均P < .001)。

核心结论

  • 癌症诊断导致青光眼患者用药依从性降低。
  • 应针对癌症负担造成的续药障碍制定政策,而非针对青光眼患者共有的风险因素。

研究设计与样本

  • 基于人群的队列研究,纳入单眼或双眼确诊青光眼且年龄≥20岁的患者。
  • 排除青光眼确诊2年内发生癌症或癌症确诊后2年内死亡的患者。
  • 无癌症青光眼患者随访至确诊癌症,并与研究期间未发生癌症的青光眼患者匹配。

主要发现

  • 癌症组1年间隔MPR为0.379(95% CI:0.370-0.388),无癌症组为0.313(95% CI:0.308-0.319)。
  • 癌症诊断后1年间隔MPR下降17.4%(P < .001)。
  • 2年间隔MPR下降10.4%(P < .001),2年平均间隔MPR下降9.21%(P < .001)。

临床怎么用

  • 对合并癌症的青光眼患者应关注其续药障碍,针对性改善用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the association between cancer diagnosis and medication adherence in patients with glaucoma. DESIGN: Cohort study. METHODS: Setting: Population-based. StudyPopulation: All patients with confirmed glaucoma in one or both eyes. All patients were aged 20 years or older. Patients who developed cancer within 2 year of a confirmed glaucoma diagnosis or who were dead within 2 year after a confirmed cancer diagnosis were excluded. Intervention orObservationProcedure(s): Individuals without cancer but with a confirmed glaucoma diagnosis were followed until they received a confirmed cancer diagnosis. They were then matched with a group of patients with confirmed glaucoma who did not develop cancer during the study period. MainOutcomeMeasure(s): Secondary adherence measured using medication possession ratio (MPR) at 1-year, 2-year, and 2-year-average intervals. RESULTS: For both patients with cancer and their matches, MPR was the highest when measured at 1-year intervals. MPR was 0.379 (95% CI: 0.370-0.388) for the cancer group and 0.313 (95% CI: 0.308-0.319) for the cancer-free group. MPR measured using 1-year intervals decreased by 17.4% after cancer diagnosis (P < .001). MPR measured using 2-year and 2-year-average intervals decreased by 10.4% (P < .001) and 9.21% (P < .001), respectively. CONCLUSIONS: Cancer diagnosis leads to lower medication adherence in patients with glaucoma. To improve medication adherence in patients with glaucoma who also have cancer, policies should directly target the burden associated with having cancer that tends to create barriers for medication refills, rather than targeting risk factors that are also applicable to patients with glaucoma but without cancer.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hou CH, Lin KK, Lee JS, et al. Medication Adherence in Patients With Glaucoma After Cancer Diagnosis. Am J Ophthalmol. 2020. PMID: 31945329. doi:10.1016/j.ajo.2020.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。